You are here: Industry Insights > Non-Metastatic

News List

Janssen announces European Commission approval of ERLEADA (apalutamide) for non-metastatic castration-resistant prostate cancer patients who are at high risk of developing metastatic disease firstwordpharma
January 17, 2019
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the European Commission (EC) has granted marketing authorisation for ERLEADA® (apalutamide), a next generation oral androgen receptor inhibitor for the treatment of adult patie
Janssen announces European Commission approval of ERLEADA (apalutamide) for non-metastatic castration-resistant prostate cancer patients who are at high risk of developing metastatic disease firstwordpharma
January 17, 2019
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the European Commission (EC) has granted marketing authorisation for ERLEADA® (apalutamide), a next generation oral androgen receptor inhibitor for the treatment of adult patie
the First and Only Oral Treatment for Men with Non-Metastatic and Metastatic Castration-Resistant Prostate Cancer firstwordpharma
January 15, 2019
Astellas Pharma Canada, Inc., today announced that Health Canada approved an expanded indication for enzalutamide, an androgen receptor inhibitor for the treatment of patients with prostate cancer, following a Priority Review by Health Canada's Therapeuti